Health Minister Tyler Shandro announced Alberta is working with Novartis Pharmaceuticals Canada Inc. to provide interim access to Zolgensma for children suffering from spinal muscular atrophy (SMA) — a rare and progressive genetic disorder that causes muscle wasting. Kim Smith has more on Global News at Noon Edmonton.
Global News at Noon Edmonton
Alberta children with spinal muscular atrophy eligible for interim access to Zolgensma
More Videos
-
University of Alberta Agriculture Club preparing for annual charity concert
-
Edmonton Oil Kings unveil special Teddy Bear Toss jerseys
-
Renewed push underway to save old Royal Alberta Museum building
-
Edmonton fiddle player talks about what led her to becoming a musician
-
Alberta government forecasts $4.6B surplus in budget update
-
Conservatives call on Boissonneault to resign
You are viewing an Accelerated Mobile Webpage.
View Original Article